University of Leicester   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Leicester United Kingdom (1921)

Organization Overview

First Clinical Trial
1993
NCT00003804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Academic Clinical Lecturer in Cardiac Surgery, University of Leicester | Associate Professor, University of Leicester | BHF Professor of Cardiac Surgery, University of Leicester | Children's Hospital, Leicester | Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX | Department of Cardiovascular Sciences, University of Leicester British Heart Foundation Cardiovascular Research Centre | Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, United Kingdom LE5 4PW | East Park Medical Centre, Leicester NHS Trust | East Park Medical Centre, NHS trust, Leicester | Glenfield Hospital | Leicester Clinical Trials Unit | Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK | Leicester General Hospital | Leicester General Hospital, Leicester | Leicester General Hospital, University Hospitals of Leicester NHS Trust | Univeristy of Leicester | University Hospital of Leicester NHS Tust | University Hospitals, Leicester | University of Leicester | University of Leicester, Leicester, United Kingdom | University of Leicester & Leicester University Hospitals | University of Leicester, United Kingdom | University of Leicester/University Hospitals Leicester | University of Leicester/University Hospitals of Leicester NHS Trust | Univesrity of Leicester

Active Ingredients

Drugs in Phase 4 Trials (16)

amiloride (midamor) (1 trial)

canagliflozin (invokana) (1 trial)

ciclesonide (alvesco) (1 trial)

dapagliflozin (farxiga) (2 trials)

donepezil (aricept) (1 trial)

empagliflozin (jardiance) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

fluticasone (cutivate) (1 trial)

gliclazide (1 trial)

glimepiride (amaryl) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

liraglutide (victoza) (3 trials)

pioglitazone (actos) (2 trials)

prednisone (meticorten) (1 trial)

repaglinide (prandin) (1 trial)

sufonylurea (1 trial)

Drugs in Phase 3 Trials (24)

autologous hematopoietic cell (1 trial)

blood plasma (1 trial)

busulfan (myleran) (2 trials)

carboplatin (paraplatin) (5 trials)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (2 trials)

dactinomycin (cosmegen) (3 trials)

dinutuximab (unituxin) (1 trial)

doxorubicin (Doxil) (4 trials)

etoposide (vepesid) (3 trials)

ifosfamide (ifex) (1 trial)

isotretinoin (accutane) (1 trial)

lomustine (1 trial)

mannitol (1 trial)

melphalan (alkeran) (2 trials)

mepolizumab (Nucala) (1 trial)

methylprednisolone (medrol) (1 trial)

montelukast (singulair) (1 trial)

nivolumab (opdivo) (1 trial)

peripheral blood hematopoietic cell (1 trial)

sargramostim (leukine) (1 trial)

sitagliptin (januvia) (1 trial)

theostene (1 trial)

vincristine (oncovin) (5 trials)

Drugs in Phase 2 Trials (35)

abemaciclib (verzenio) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

adenosine (Adenocard) (1 trial)

aflunov (1 trial)

atezolizumab (tecentriq) (1 trial)

atorvastatin (lipitor) (1 trial)

avelumab (bavencio) (1 trial)

bemcentinib (1 trial)

bevacizumab (avastin) (1 trial)

bivalirudin (angiomax) (1 trial)

cediranib (1 trial)

curcumin (2 trials)

defactinib (1 trial)

fish oil (Omegavan) (4 trials)

fluorouracil (efudex) (2 trials)

ganetespib (1 trial)

gemcitabine (gemzar) (1 trial)

gwp42004 (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (2 trials)

mrx-4dp0004 (1 trial)

mstt1041a (1 trial)

neramexane mesylate (1 trial)

niraparib (zejula) (1 trial)

nitroprusside (nipride) (1 trial)

olaparib (lynparza) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (1 trial)

rucaparib (rubraca) (1 trial)

sparsentan (1 trial)

tezepelumab (1 trial)

valproic acid (depakene) (1 trial)

vinorelbine (navelbine) (1 trial)

zibotentan (1 trial)

Drugs in Phase 1 Trials (6)

albuterol (proventil) (1 trial)

daunoxome (1 trial)

inactivated influenza vaccine (3 trials)

potassium alum (1 trial)

sildenafil (viagra) (1 trial)

supraene (1 trial)

Drugs in Other Trials (9)

acetic acid (vosol) (1 trial)

beetroot juice (1 trial)

etanercept (enbrel) (1 trial)

lidocaine (xylocaine) (1 trial)

melatonin (1 trial)

piper longum (1 trial)

prilocaine (citanest) (1 trial)

tinospora (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 1)

Alzheimer Disease (Phase 4)

Asthma (Phase 4)

Autoimmune Diseases (Phase 2)

Breast Neoplasms (Phase 1)

Bronchial Diseases (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cardiovascular Diseases (Phase 3)

Central Nervous System Neoplasms (Phase 3)

Cicatrix (Phase 1)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 2)

Cough (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Eosinophilia (Phase 3)

Esophageal Neoplasms (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Granulomatosis with Polyangiitis (Phase 3)

Heart Valve Diseases (Phase 2)

Hepatoblastoma (Phase 2)

Hypersensitivity (Phase 2)

Hypersensitivity, Immediate (Phase 2)

Hypertension (Phase 4)

Immune System Diseases (Phase 2)

Infarction (Phase 2)

Inflammation (Phase 2)

Influenza, Human (Phase 2)

Kidney Diseases (Phase 2)

Kidney Neoplasms (Phase 3)

Liver Neoplasms (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Medulloblastoma (Phase 3)

Mesothelioma (Phase 3)

Microscopic Polyangiitis (Phase 3)

Multiple Organ Failure (Phase 2)

Myocardial Infarction (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Second Primary (Phase 2)

Nephrosis (Phase 4)

Nephrotic Syndrome (Phase 4)

Nervous System Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Nystagmus, Congenital (Phase 2)

Nystagmus, Pathologic (Phase 2)

Obesity (Phase 4)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pancreatitis (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Hypersensitivity (Phase 2)

Respiratory Sounds (Phase 3)

Respiratory Tract Diseases (Phase 2)

Sarcoma (Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Vasculitis (Phase 3)

Weight Loss (Phase 4)

Wilms Tumor (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial APIs: 90